Tissue Protecting Antidotes From Anti-Apoptotic Factors of Mycoplasma
Final rept. 8 Nov 2004-7 Aug 2005
CLEVELAND BIOLABS INC (CBL) CLEVELAND OH
Pagination or Media Count:
The major goal of the program is identification of novel radioprotectants of Mycoplasma origin. The program consisted of two branches screening of Mycoplasma strains for anti-apoptotic factors and testing of predicted candidates for radioprotective activity. Both approaches were successfully implemented and yielded positive results. First, we have found and are currently characterizing a strong anti-apoptotic activity in the lysates of M. arginini. Second, an extremely potent radioprotectant, named CBLB601, structurally related to Mycoplasma lipopeptides was discovered. We have optimized CBLB601 administration regime for reaching maximal radioprotection as well as embarked upon characterization of its toxicological and pharmacological profiles. CBLB601 showed remarkable efficacy, being capable of protecting 100 of treated mice from supralethal 10Gy total body irradiation dose with evident rescuing lymphoid organs. Initial structure-function analysis of CBLB601 led to the understanding that radioprotection is conferred by stimulation of TLR2TLR6 but not TLR2TLR1 dimers.
- Chemical, Biological and Radiological Warfare